Global Localized Scleroderma Market
Global Localized Scleroderma Market

Localized Scleroderma Comprehensive Study by Type (Morphea, Linear Scleroderma), Treatment (Creams, Ointments, Phototherapy, Steroids, Medication), End-users (Hospitals, Clinics, Others), Distribution Channel (Online Channels, Offline Channels), Diagnosis (Skin Examination, MRI, Ultrasound, Skin Biopsy, Blood Tests) Players and Region - Global Market Outlook to 2025

Localized Scleroderma Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 241 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Localized Scleroderma Market?

It is estimated that up to three in every 100,000 people are diagnosed with localized scleroderma every year. This is more common in women compared to men. Localized scleroderma is characterized by the thickening of the skin from excessive collagen deposits, which lead to the appearance of thick, hard patches. It can be divided into two groups depending on the shape and area of skin affected, morphea and linear scleroderma. The morphea is characterized by thick, hard patches of skin that are white or yellow, and ringed with a purplish halo that may itch but is usually not painful and in linear scleroderma, there are thickened streaks of skin rather than patches, which more commonly extend deep into the skin.

The market study is being classified by Type (Morphea and Linear Scleroderma) and major geographies with country level break-up.

Actelion Pharmaceuticals, Inc. (Switzerland), Boehringer Ingelheim (Germany), Bayer AG (Germany), Cytori Therapeutics, Inc. (United States), Cumberland Pharmaceuticals Inc. (United States), Gilead Sciences, Inc. (United States), Pfizer Inc. (United States), Active Biotech AB (Sweden), BioLineRx, Ltd. (Israel) and Bristol-Myers Squibb Company (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are GenKyoTex SA (France) and Corbus Pharmaceuticals Holdings, Inc. (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Localized Scleroderma market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Localized Scleroderma market by Type, Application and Region.

On the basis of geography, the market of Localized Scleroderma has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Incidences of Localized Scleroderma
  • Increasing Number of Hospitals and Clinics

Market Trend
  • Increasing Number of Research Activities
  • Robust Increase in the Distribution Channels

Restraints
  • Less Awareness about Localized Scleroderma

Opportunities
  • Growing Target Patient Population
  • Growth in the Healthcare Industry

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Localized Scleroderma Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Morphea
  • Linear Scleroderma
By Treatment
  • Creams
  • Ointments
  • Phototherapy
  • Steroids
  • Medication

By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Online Channels
  • Offline Channels

By Diagnosis
  • Skin Examination
  • MRI
  • Ultrasound
  • Skin Biopsy
  • Blood Tests

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidences of Localized Scleroderma
      • 3.2.2. Increasing Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Research Activities
      • 3.4.2. Robust Increase in the Distribution Channels
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Localized Scleroderma, by Type, Treatment, End-users, Distribution Channel, Diagnosis and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Localized Scleroderma (Value)
      • 5.2.1. Global Localized Scleroderma by: Type (Value)
        • 5.2.1.1. Morphea
        • 5.2.1.2. Linear Scleroderma
      • 5.2.2. Global Localized Scleroderma by: Treatment (Value)
        • 5.2.2.1. Creams
        • 5.2.2.2. Ointments
        • 5.2.2.3. Phototherapy
        • 5.2.2.4. Steroids
        • 5.2.2.5. Medication
      • 5.2.3. Global Localized Scleroderma by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Localized Scleroderma by: Distribution Channel (Value)
        • 5.2.4.1. Online Channels
        • 5.2.4.2. Offline Channels
      • 5.2.5. Global Localized Scleroderma by: Diagnosis (Value)
        • 5.2.5.1. Skin Examination
        • 5.2.5.2. MRI
        • 5.2.5.3. Ultrasound
        • 5.2.5.4. Skin Biopsy
        • 5.2.5.5. Blood Tests
      • 5.2.6. Global Localized Scleroderma Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Localized Scleroderma: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Actelion Pharmaceuticals, Inc. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cytori Therapeutics, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cumberland Pharmaceuticals Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Gilead Sciences, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Active Biotech AB (Sweden)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BioLineRx, Ltd. (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers Squibb Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Localized Scleroderma Sale, by Type, Treatment, End-users, Distribution Channel, Diagnosis and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Localized Scleroderma (Value)
      • 7.2.1. Global Localized Scleroderma by: Type (Value)
        • 7.2.1.1. Morphea
        • 7.2.1.2. Linear Scleroderma
      • 7.2.2. Global Localized Scleroderma by: Treatment (Value)
        • 7.2.2.1. Creams
        • 7.2.2.2. Ointments
        • 7.2.2.3. Phototherapy
        • 7.2.2.4. Steroids
        • 7.2.2.5. Medication
      • 7.2.3. Global Localized Scleroderma by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Localized Scleroderma by: Distribution Channel (Value)
        • 7.2.4.1. Online Channels
        • 7.2.4.2. Offline Channels
      • 7.2.5. Global Localized Scleroderma by: Diagnosis (Value)
        • 7.2.5.1. Skin Examination
        • 7.2.5.2. MRI
        • 7.2.5.3. Ultrasound
        • 7.2.5.4. Skin Biopsy
        • 7.2.5.5. Blood Tests
      • 7.2.6. Global Localized Scleroderma Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Localized Scleroderma: by Type(USD Million)
  • Table 2. Localized Scleroderma Morphea , by Region USD Million (2014-2019)
  • Table 3. Localized Scleroderma Linear Scleroderma , by Region USD Million (2014-2019)
  • Table 4. Localized Scleroderma: by Treatment(USD Million)
  • Table 5. Localized Scleroderma Creams , by Region USD Million (2014-2019)
  • Table 6. Localized Scleroderma Ointments , by Region USD Million (2014-2019)
  • Table 7. Localized Scleroderma Phototherapy , by Region USD Million (2014-2019)
  • Table 8. Localized Scleroderma Steroids , by Region USD Million (2014-2019)
  • Table 9. Localized Scleroderma Medication , by Region USD Million (2014-2019)
  • Table 10. Localized Scleroderma: by End-users(USD Million)
  • Table 11. Localized Scleroderma Hospitals , by Region USD Million (2014-2019)
  • Table 12. Localized Scleroderma Clinics , by Region USD Million (2014-2019)
  • Table 13. Localized Scleroderma Others , by Region USD Million (2014-2019)
  • Table 14. Localized Scleroderma: by Distribution Channel(USD Million)
  • Table 15. Localized Scleroderma Online Channels , by Region USD Million (2014-2019)
  • Table 16. Localized Scleroderma Offline Channels , by Region USD Million (2014-2019)
  • Table 17. Localized Scleroderma: by Diagnosis(USD Million)
  • Table 18. Localized Scleroderma Skin Examination , by Region USD Million (2014-2019)
  • Table 19. Localized Scleroderma MRI , by Region USD Million (2014-2019)
  • Table 20. Localized Scleroderma Ultrasound , by Region USD Million (2014-2019)
  • Table 21. Localized Scleroderma Skin Biopsy , by Region USD Million (2014-2019)
  • Table 22. Localized Scleroderma Blood Tests , by Region USD Million (2014-2019)
  • Table 23. South America Localized Scleroderma, by Country USD Million (2014-2019)
  • Table 24. South America Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 25. South America Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 26. South America Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 27. South America Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 28. South America Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 29. Brazil Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 30. Brazil Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 31. Brazil Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 32. Brazil Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 33. Brazil Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 34. Argentina Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 35. Argentina Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 36. Argentina Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 37. Argentina Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 38. Argentina Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 39. Rest of South America Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 40. Rest of South America Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 41. Rest of South America Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 42. Rest of South America Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 43. Rest of South America Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 44. Asia Pacific Localized Scleroderma, by Country USD Million (2014-2019)
  • Table 45. Asia Pacific Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 46. Asia Pacific Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 47. Asia Pacific Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 48. Asia Pacific Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 49. Asia Pacific Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 50. China Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 51. China Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 52. China Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 53. China Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 54. China Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 55. Japan Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 56. Japan Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 57. Japan Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 58. Japan Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 59. Japan Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 60. India Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 61. India Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 62. India Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 63. India Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 64. India Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 65. South Korea Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 66. South Korea Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 67. South Korea Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 68. South Korea Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 69. South Korea Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 70. Taiwan Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 71. Taiwan Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 72. Taiwan Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 73. Taiwan Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 74. Taiwan Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 75. Australia Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 76. Australia Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 77. Australia Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 78. Australia Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 79. Australia Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 80. Rest of Asia-Pacific Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 81. Rest of Asia-Pacific Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 82. Rest of Asia-Pacific Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 83. Rest of Asia-Pacific Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 84. Rest of Asia-Pacific Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 85. Europe Localized Scleroderma, by Country USD Million (2014-2019)
  • Table 86. Europe Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 87. Europe Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 88. Europe Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 89. Europe Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 90. Europe Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 91. Germany Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 92. Germany Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 93. Germany Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 94. Germany Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 95. Germany Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 96. France Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 97. France Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 98. France Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 99. France Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 100. France Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 101. Italy Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 102. Italy Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 103. Italy Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 104. Italy Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 105. Italy Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 106. United Kingdom Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 107. United Kingdom Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 108. United Kingdom Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 109. United Kingdom Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 110. United Kingdom Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 111. Netherlands Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 112. Netherlands Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 113. Netherlands Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 114. Netherlands Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 115. Netherlands Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 116. Rest of Europe Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 117. Rest of Europe Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 118. Rest of Europe Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 119. Rest of Europe Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 120. Rest of Europe Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 121. MEA Localized Scleroderma, by Country USD Million (2014-2019)
  • Table 122. MEA Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 123. MEA Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 124. MEA Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 125. MEA Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 126. MEA Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 127. Middle East Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 128. Middle East Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 129. Middle East Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 130. Middle East Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 131. Middle East Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 132. Africa Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 133. Africa Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 134. Africa Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 135. Africa Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 136. Africa Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 137. North America Localized Scleroderma, by Country USD Million (2014-2019)
  • Table 138. North America Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 139. North America Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 140. North America Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 141. North America Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 142. North America Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 143. United States Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 144. United States Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 145. United States Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 146. United States Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 147. United States Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 148. Canada Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 149. Canada Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 150. Canada Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 151. Canada Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 152. Canada Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 153. Mexico Localized Scleroderma, by Type USD Million (2014-2019)
  • Table 154. Mexico Localized Scleroderma, by Treatment USD Million (2014-2019)
  • Table 155. Mexico Localized Scleroderma, by End-users USD Million (2014-2019)
  • Table 156. Mexico Localized Scleroderma, by Distribution Channel USD Million (2014-2019)
  • Table 157. Mexico Localized Scleroderma, by Diagnosis USD Million (2014-2019)
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Localized Scleroderma: by Type(USD Million)
  • Table 169. Localized Scleroderma Morphea , by Region USD Million (2020-2025)
  • Table 170. Localized Scleroderma Linear Scleroderma , by Region USD Million (2020-2025)
  • Table 171. Localized Scleroderma: by Treatment(USD Million)
  • Table 172. Localized Scleroderma Creams , by Region USD Million (2020-2025)
  • Table 173. Localized Scleroderma Ointments , by Region USD Million (2020-2025)
  • Table 174. Localized Scleroderma Phototherapy , by Region USD Million (2020-2025)
  • Table 175. Localized Scleroderma Steroids , by Region USD Million (2020-2025)
  • Table 176. Localized Scleroderma Medication , by Region USD Million (2020-2025)
  • Table 177. Localized Scleroderma: by End-users(USD Million)
  • Table 178. Localized Scleroderma Hospitals , by Region USD Million (2020-2025)
  • Table 179. Localized Scleroderma Clinics , by Region USD Million (2020-2025)
  • Table 180. Localized Scleroderma Others , by Region USD Million (2020-2025)
  • Table 181. Localized Scleroderma: by Distribution Channel(USD Million)
  • Table 182. Localized Scleroderma Online Channels , by Region USD Million (2020-2025)
  • Table 183. Localized Scleroderma Offline Channels , by Region USD Million (2020-2025)
  • Table 184. Localized Scleroderma: by Diagnosis(USD Million)
  • Table 185. Localized Scleroderma Skin Examination , by Region USD Million (2020-2025)
  • Table 186. Localized Scleroderma MRI , by Region USD Million (2020-2025)
  • Table 187. Localized Scleroderma Ultrasound , by Region USD Million (2020-2025)
  • Table 188. Localized Scleroderma Skin Biopsy , by Region USD Million (2020-2025)
  • Table 189. Localized Scleroderma Blood Tests , by Region USD Million (2020-2025)
  • Table 190. South America Localized Scleroderma, by Country USD Million (2020-2025)
  • Table 191. South America Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 192. South America Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 193. South America Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 194. South America Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 195. South America Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 196. Brazil Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 197. Brazil Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 198. Brazil Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 199. Brazil Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 200. Brazil Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 201. Argentina Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 202. Argentina Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 203. Argentina Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 204. Argentina Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 205. Argentina Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 206. Rest of South America Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 207. Rest of South America Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 208. Rest of South America Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 209. Rest of South America Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 210. Rest of South America Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 211. Asia Pacific Localized Scleroderma, by Country USD Million (2020-2025)
  • Table 212. Asia Pacific Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 213. Asia Pacific Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 214. Asia Pacific Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 215. Asia Pacific Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 216. Asia Pacific Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 217. China Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 218. China Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 219. China Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 220. China Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 221. China Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 222. Japan Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 223. Japan Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 224. Japan Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 225. Japan Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 226. Japan Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 227. India Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 228. India Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 229. India Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 230. India Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 231. India Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 232. South Korea Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 233. South Korea Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 234. South Korea Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 235. South Korea Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 236. South Korea Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 237. Taiwan Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 238. Taiwan Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 239. Taiwan Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 240. Taiwan Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 241. Taiwan Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 242. Australia Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 243. Australia Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 244. Australia Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 245. Australia Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 246. Australia Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 247. Rest of Asia-Pacific Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 248. Rest of Asia-Pacific Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 249. Rest of Asia-Pacific Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 250. Rest of Asia-Pacific Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 251. Rest of Asia-Pacific Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 252. Europe Localized Scleroderma, by Country USD Million (2020-2025)
  • Table 253. Europe Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 254. Europe Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 255. Europe Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 256. Europe Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 257. Europe Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 258. Germany Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 259. Germany Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 260. Germany Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 261. Germany Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 262. Germany Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 263. France Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 264. France Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 265. France Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 266. France Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 267. France Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 268. Italy Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 269. Italy Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 270. Italy Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 271. Italy Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 272. Italy Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 273. United Kingdom Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 274. United Kingdom Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 275. United Kingdom Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 276. United Kingdom Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 277. United Kingdom Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 278. Netherlands Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 279. Netherlands Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 280. Netherlands Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 281. Netherlands Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 282. Netherlands Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 283. Rest of Europe Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 284. Rest of Europe Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 285. Rest of Europe Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 286. Rest of Europe Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 287. Rest of Europe Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 288. MEA Localized Scleroderma, by Country USD Million (2020-2025)
  • Table 289. MEA Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 290. MEA Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 291. MEA Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 292. MEA Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 293. MEA Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 294. Middle East Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 295. Middle East Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 296. Middle East Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 297. Middle East Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 298. Middle East Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 299. Africa Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 300. Africa Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 301. Africa Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 302. Africa Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 303. Africa Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 304. North America Localized Scleroderma, by Country USD Million (2020-2025)
  • Table 305. North America Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 306. North America Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 307. North America Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 308. North America Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 309. North America Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 310. United States Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 311. United States Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 312. United States Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 313. United States Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 314. United States Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 315. Canada Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 316. Canada Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 317. Canada Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 318. Canada Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 319. Canada Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 320. Mexico Localized Scleroderma, by Type USD Million (2020-2025)
  • Table 321. Mexico Localized Scleroderma, by Treatment USD Million (2020-2025)
  • Table 322. Mexico Localized Scleroderma, by End-users USD Million (2020-2025)
  • Table 323. Mexico Localized Scleroderma, by Distribution Channel USD Million (2020-2025)
  • Table 324. Mexico Localized Scleroderma, by Diagnosis USD Million (2020-2025)
  • Table 325. Research Programs/Design for This Report
  • Table 326. Key Data Information from Secondary Sources
  • Table 327. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Localized Scleroderma: by Type USD Million (2014-2019)
  • Figure 5. Global Localized Scleroderma: by Treatment USD Million (2014-2019)
  • Figure 6. Global Localized Scleroderma: by End-users USD Million (2014-2019)
  • Figure 7. Global Localized Scleroderma: by Distribution Channel USD Million (2014-2019)
  • Figure 8. Global Localized Scleroderma: by Diagnosis USD Million (2014-2019)
  • Figure 9. South America Localized Scleroderma Share (%), by Country
  • Figure 10. Asia Pacific Localized Scleroderma Share (%), by Country
  • Figure 11. Europe Localized Scleroderma Share (%), by Country
  • Figure 12. MEA Localized Scleroderma Share (%), by Country
  • Figure 13. North America Localized Scleroderma Share (%), by Country
  • Figure 14. Global Localized Scleroderma share by Players 2019 (%)
  • Figure 15. Global Localized Scleroderma share by Players (Top 3) 2019(%)
  • Figure 16. Global Localized Scleroderma share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Actelion Pharmaceuticals, Inc. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Actelion Pharmaceuticals, Inc. (Switzerland) Revenue: by Geography 2019
  • Figure 20. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Boehringer Ingelheim (Germany) Revenue: by Geography 2019
  • Figure 22. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 24. Cytori Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Cytori Therapeutics, Inc. (United States) Revenue: by Geography 2019
  • Figure 26. Cumberland Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Cumberland Pharmaceuticals Inc. (United States) Revenue: by Geography 2019
  • Figure 28. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Gilead Sciences, Inc. (United States) Revenue: by Geography 2019
  • Figure 30. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 32. Active Biotech AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 33. Active Biotech AB (Sweden) Revenue: by Geography 2019
  • Figure 34. BioLineRx, Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 35. BioLineRx, Ltd. (Israel) Revenue: by Geography 2019
  • Figure 36. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 37. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2019
  • Figure 38. Global Localized Scleroderma: by Type USD Million (2020-2025)
  • Figure 39. Global Localized Scleroderma: by Treatment USD Million (2020-2025)
  • Figure 40. Global Localized Scleroderma: by End-users USD Million (2020-2025)
  • Figure 41. Global Localized Scleroderma: by Distribution Channel USD Million (2020-2025)
  • Figure 42. Global Localized Scleroderma: by Diagnosis USD Million (2020-2025)
  • Figure 43. South America Localized Scleroderma Share (%), by Country
  • Figure 44. Asia Pacific Localized Scleroderma Share (%), by Country
  • Figure 45. Europe Localized Scleroderma Share (%), by Country
  • Figure 46. MEA Localized Scleroderma Share (%), by Country
  • Figure 47. North America Localized Scleroderma Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Actelion Pharmaceuticals, Inc. (Switzerland)
  • Boehringer Ingelheim (Germany)
  • Bayer AG (Germany)
  • Cytori Therapeutics, Inc. (United States)
  • Cumberland Pharmaceuticals Inc. (United States)
  • Gilead Sciences, Inc. (United States)
  • Pfizer Inc. (United States)
  • Active Biotech AB (Sweden)
  • BioLineRx, Ltd. (Israel)
  • Bristol-Myers Squibb Company (United States)
Additional players considered in the study are as follows:
GenKyoTex SA (France) , Corbus Pharmaceuticals Holdings, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation